Reviva Pharmaceuticals Holdings, Inc. (RVPH) has priced its public offering of 6.66 million shares at $1.50 each, aiming to raise approximately $10 million. The offering includes series G and H warrants, both with an exercise price of $1.50. Following the announcement, RVPH’s stock plummeted 33.16% to $1.25 in after-hours trading, reflecting investor concerns over dilution and the company’s current valuation.

This capital raise is critical for Reviva as it seeks to fund its RECOVER-2 Phase 3 trial for Brilaroxazine, a treatment for schizophrenia, alongside other R&D and operational needs. The stock has seen significant volatility, trading between $1.82 and $23.4 over the past year, highlighting the market’s sensitivity to news related to its pipeline and financial health.

For market professionals, the implications of this offering and the stock’s sharp decline warrant close attention, especially as Reviva navigates its clinical development path. For further insights, I recommend checking out the full article at RTTNews.

Source: nasdaq.com